About the Conference
The Trans-Pacific Health Sciences Dialogue is a meeting for C-level biopharmaceutical industry executives and business development executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.
This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
In 2015, the Trans-Pacific Health Sciences Dialogue will be held at:
Joseph B. Martin Conference Center
at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an event for senior biopharmaceutical executives, KOLs, select industry advisors and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment.
Industry News from FiercePharmaAsia
- No artful tax dodging here, drug firms tell Australia transfer-price inquiry
We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.
Industry News from PharmAsia
- Second Asian Deal Helps Resurrect Ablynx’s OzoralizumabBelgium's Ablynx has chosen Taisho as its partner for the development in Japan of a nanobody therapy for rheumatoid arthritis, marking both the first step towards a commercial presence for Ablynx in the country and the second Asian licensing deal for the formerly shelved molecule.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/HvdzHEt82tw" height="1" width="1" alt="" />